Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Race Oncology has announced the appointments of Dr. Jose Iglesias as Chief Medical Officer and Dr. Simon Fisher as Vice President of Clinical, both bringing extensive experience in oncology and pharmaceutical leadership. These appointments are expected to significantly enhance Race’s clinical leadership and strategic capabilities, particularly in advancing the development of their oncology drug, RC220, which aims to address significant gaps in patient care and improve outcomes in cancer treatment.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a clinical stage biopharmaceutical company focused on cancer care, listed on the Australian Securities Exchange. The company’s lead product, bisantrene, is an anticancer drug known for its therapeutic benefits and reduced cardiotoxicity compared to traditional anthracyclines. Race is developing a reformulated version, RC220, targeting unmet needs in oncology, particularly in combination with anthracyclines for solid tumors and as a treatment for acute myeloid leukemia.
YTD Price Performance: -10.37%
Average Trading Volume: 118,424
Technical Sentiment Signal: Hold
Current Market Cap: A$210.2M
See more insights into RAC stock on TipRanks’ Stock Analysis page.